Ziru Pharmaceuticals, Haussen Pharmaceuticals injection boron tazome through a consistent evaluation

On October 29th, the official website of the State Drug Administration showed that the injection boron tazami of two companies, Qilu Pharmaceuticals and Howson Pharmaceuticals, had been evaluated consistently through supplementary applications.
, the drug evaluation manufacturers have reached three.
is a new type of protease competitive inhibitor, clinically mainly used for multiple myeloma and sleeve lymphoma.
the drug was originally developed by Millennium (later acquired by Takeda) and approved by the FDA in May 2003 under the name Velcade.
January 2005, the drug was approved in China and the product was named Wan Yu.
boron tezome is a Category B catalogue product for national health insurance.
2018 results, Takeda's U.S. sales were 127.9 billion yen ($1,195 million) and Johnson and Johnson's sales outside the U.S. were $1.116 billion.
source: Pharmaceutical Rubik's Cube NextPharma has previously had 8 enterprises producing and selling injectable boron tazome, of which, Stone Pharmaceutical Group declared the drug in category 4 was approved in June 2020, and as if through a consistent evaluation.
Pharmaceuticals and Howson Pharmaceuticals passed a consistent evaluation through a supplementary application.